NDA 213687 · Ultragenyx Pharm INC
Dojolvi
Triheptanoin · Oral · Medium-chain Triglyceride
NovelOrphanLast checked: Nov 20, 2026Latest source record: Oct 30, 2023 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2020
Jun 30, 2020
Approved uses
1
Original approval plus efficacy supplements
Registered trials
32
2 Phase 3, 1 recruiting
FAERS reports
554
350 serious, 69 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Jun 10, 2025.
DOJOLVI is indicated as a source of calories and fatty acids for the treatment of adult and pediatric patients with molecularly confirmed long-chain fatty acid oxidation disorders (LC-FAOD). DOJOLVI is a medium-chain triglyceride indicated as a source of calories and fatty acids for the treatment of adult and pediatric patients with molecularly confirmed long-chain fatty acid oxidation disorders (LC-FAOD).
Mechanism: Triheptanoin is a medium-chain triglyceride consisting of three odd-chain 7-carbon length fatty acids (heptanoate) that provide a source of calories and fatty acids to bypass the long-chain FAOD enzyme deficiencies for energy production and replacement.
Therapeutic areas: Cardiovascular and metabolic
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
1 products under this application
- DOJOLVI · TRIHEPTANOIN 100% w/w · LIQUID, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Triheptanoin" as an intervention, any sponsor and status, largest first.
- A Comparative Phase 2 Study Assessing the Efficacy of Triheptanoin, an Anaplerotic Therapy in Huntington's DiseasePivotal-lookingCompleted
Institut National de la Santé Et de la Recherche Médicale, FranceGovernment (non-federal)
NCT02453061 · 100 participants · Start Jun 29, 2015 · Primary completion Dec 3, 2019
Drug: Triheptanoin oil; Placebo · For: Huntington Disease
Sites: Paris, France; Leiden, Netherlands
Ultragenyx Pharmaceutical IncIndustry
NCT02214160 · 94 participants · Start Dec 9, 2014 · Primary completion Dec 3, 2020
Drug: UX007 · For: Carnitine Palmitoyltransferase (CPT I or CPT II) Deficiency; Very Long Chain Acyl-CoA Dehydrogenase (VLCAD) Deficiency; Long-chain 3-hydroxy-acyl-CoA Dehydrogenase (LCHAD) Deficiency and 2 more
Sites: San Francisco, California; Washington D.C., District of Columbia; Tampa, Florida · 11 sites in all
- A Study to Determine the Effect of Triheptanoin Compared With Even-Chain MCT on MCEs in Pediatric Patients With LC-FAODPivotal-lookingActive, not recruiting
Ultragenyx Pharmaceutical IncIndustry
NCT05933200 · 69 participants · Start Feb 28, 2023 · Primary completion Aug 2027
Drug: Triheptanoin · For: Long-chain Fatty Acid Oxidation Disorders (LC-FAOD)
Sites: Prague, Czechia; Freiburg im Breisgau, Germany; Bunkyo City, Japan · 15 sites in all
University of Texas Southwestern Medical CenterAcademic, hospital or other
NCT03181399 · 45 participants · Start Apr 18, 2018 · Primary completion Sep 10, 2023
Drug: Triheptanoin · For: GLUT1DS1; Epilepsy; Glut1 Deficiency Syndrome 1, Autosomal Recessive and 4 more
Sites: Dallas, Texas
Ultragenyx Pharmaceutical IncIndustry
NCT01993186 · 36 participants · Start Feb 28, 2014 · Primary completion Sep 20, 2017
Drug: UX007; Placebo · For: Glucose Transporter Type 1 Deficiency Syndrome (Glut1 DS)
Sites: Aurora, Colorado; Miami, Florida; Orlando, Florida · 14 sites in all
Oregon Health and Science UniversityAcademic, hospital or other
NCT01379625 · 32 participants · Start Sep 2011 · Primary completion Apr 2015
Drug: Triheptanoin · For: Very Long-chain acylCoA Dehydrogenase (VLCAD) Deficiency; Carnitine Palmitoyltransferase 2 (CPT2) Deficiency; Mitochondrial Trifunctional Protein (TFP) Deficiency and 1 more
Sites: Portland, Oregon; Pittsburgh, Pennsylvania
Ultragenyx Pharmaceutical IncIndustry
NCT01886378 · 29 participants · Start Feb 6, 2014 · Primary completion Aug 25, 2016
Drug: UX007 · For: Long-chain Fatty Acid Oxidation Disorders (LC-FAOD); Carnitine Palmitoyltransferase (CPT II) Deficiency; Very Long Chain Acyl-CoA Dehydrogenase (VLCAD) Deficiency and 2 more
Sites: Washington D.C., District of Columbia; Tampa, Florida; Chicago, Illinois · 10 sites in all
Baylor Research InstituteAcademic, hospital or other
NCT00947960 · 23 participants · Start Jun 2009 · Primary completion Jul 2015
Drug: Triheptanoin · For: Adult Polyglucosan Body Disease; Glycogen Brancher Enzyme Deficiency; Glycogen Storage Disease Type IV
Sites: Paris, France
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- vomiting88
- diarrhoea77
- rhabdomyolysis56
- off label use53
- abdominal pain upper44
- abdominal discomfort36
- blood creatine phosphokinase increased35
- death33
- nausea29
- illness25
- gastrointestinal disorder24
- hospitalisation24
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2020 | 27 |
| 2021 | 90 |
| 2022 | 117 |
| 2023 | 114 |
| 2024 | 99 |
| 2025 | 67 |
| 2026 | 40 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Dojolvi (TriHEPtanoin)
2024 spending
$2.9M
Beneficiaries
19
140 claims
Per beneficiary
$151,602
$11.34 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $0 |
| 2021 | $1,425,380 |
| 2022 | $2,240,768 |
| 2023 | $2,635,754 |
| 2024 | $2,880,438 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Triheptanoin for the treatment of long-chain fatty acid oxidation disorders: Final results of an open-label, long-term extension study.
Vockley J, Burton BK, Berry G, et al. · J Inherit Metab Dis 2023 · Clinical Trial, Research Support, Non-U.S. Gov't
- No effect of triheptanoin in patients with phosphofructokinase deficiency.
Raaschou-Pedersen DE, Madsen KL, Løkken N, et al. · Neuromuscul Disord 2022 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Effects of triheptanoin (UX007) in patients with long-chain fatty acid oxidation disorders: Results from an open-label, long-term extension study.
Vockley J, Burton B, Berry G, et al. · J Inherit Metab Dis 2021 · Clinical Trial, Phase II, Multicenter Study
- No effect of triheptanoin on exercise performance in McArdle disease.
Madsen KL, Laforêt P, Buch AE, et al. · Ann Clin Transl Neurol 2019 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Triheptanoin dramatically reduces paroxysmal motor disorder in patients with GLUT1 deficiency.
Mochel F, Hainque E, Gras D, et al. · J Neurol Neurosurg Psychiatry 2016 · Clinical Trial, Research Support, Non-U.S. Gov't
- Triheptanoin improves brain energy metabolism in patients with Huntington disease.
Adanyeguh IM, Rinaldi D, Henry PG, et al. · Neurology 2015 · Clinical Trial, Research Support, N.I.H., Extramural
Sponsor: Ultragenyx Pharm INC
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.